Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab

Journal of the American Dental Association

Volumn 142, Issue 5, 2011, Pages 506-513

  Francini, Filippo ^a   Pascucci, Alessandra ^a   Francini, Edoardo ^a   Miano, Salvatora Tindara ^a   Bargagli, Cianluca ^a   Ruggiero, Grazia ^a   Petrioli, Roberto ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

B.evacizumab.; B.isphosphonates.; Bone m.arkers.; Bone m.etastases.; Osteonecrosis of the j.aw.; Zoledronic acid

Indexed keywords

EID: 79958144849     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2011.0220     Document Type: Article

References (27)

1. Francini G, Gonnelli S, Petrioli R, Conti F, Paffetti P, Gennari C. Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 1992;10(4):591-598.
2. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19(3):420-432.
3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115-1117. (Pubitemid 37064711)
4. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527-534. (Pubitemid 38542516)
5. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates (published correction appears in N Engl J Med 2005;353[25]:2728). N Engl J Med 2005;353(1):99-102.
6. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving rV bisphosphonates. Oncology (Williston Park) 2006;2(X9):1053-1062. (Pubitemid 46940833)
7. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws (published correction appears in Ann Intern Med 2006;145[3]:235). Ann Intern Med 2006;144(10): 753-761. (Pubitemid 46780635)
8. Migliorati CA, Woo SB, Hewson I, et al. A systematic review of I bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 2010;18(8):1099-1106.
9. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580-8587. (Pubitemid 46211499)
10. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567-1575.
11. Mashiba T, Mori S, Burr DB, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulationdegree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005;23(suppl):36-42.
12. Hellstein J, Marek C. Bisphosphonate osteochemonecrosis (bisphossy jaw): is this phossy jaw of the 21st century? J Oral MaxillofacSurg 2005;63(5):682-689. (Pubitemid 40602707)
13. Fournier P, Boissier S, Filleur S, et al Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62(22): 6538-6544. (Pubitemid 35364119)
14. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper (published correction appears in JADA 2006;137[1]:26). JADA 2005;136(12):1658-1668. (Pubitemid 41810027)
15. Panares RL, Garcia AA. Bevacizumab in the management of solid tumors,. Expert Rev Anticancer Ther 2007;7(4):433-445. (Pubitemid 46681799)
16. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302(3):1055-1061. (Pubitemid 34920226)
17. Ferretti G, Fabi A, Carlini P, et al. Zoledronic acid and angiogenesis. Clin Cancer Res 2007;13(22 pt 1):6850.
18. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials, Cancer Treat Rep 1985;69(12):1375-1381. (Pubitemid 16163075)
19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1 1982;5:649-655. (Pubitemid 13149996)
20. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91(7):968-971. (Pubitemid 44023154)
21. Hoff AO, Tbth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23(6): 826-836. (Pubitemid 351768801)
22. Francini G, Petrioli R, Gonnelli S, et al. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma. Cancer 2001;92(6):1468-1474. (Pubitemid 32947831)
23. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97(l):59-69.
24. Estilo CL, Van Poznak CH, Wiliams T, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008;13(8):9H-920.
25. Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76(3):209-211.
26. Aragon-Ching JB, Ning Y-M, Chen CC, et al. Higher incidence of osteonecrosis of the jaw (ON J) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009;27(2):221-226.
27. Wessel JH, Dodson TB, Zavras Al. Zoledronate and other risk factors associated with osteonecrosis of the jaw in cancer patients: a case-control study. J Oral Maxillofac Surg 2008;66(4):625-631. (Pubitemid 351381804)